Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug ...
Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first-in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results